Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: Potential implications for clinical guidelines

Circulation

Volumn 110, Issue 18, 2004, Pages 2824-2830

  Shai, Iris ^a,d   Rimm, Eric B ^a,b   Hankinson, Susan E ^a,b   Curhan, Gary ^b   Manson, JoAnn E ^a,b   Rifai, Nader ^c   Stampfer, Meir J ^a,b   Ma, Jing ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Coronary disease; Lipids; Women

Indexed keywords

APOLIPOPROTEIN B100; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; STANDARDIZATION;

ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; INCIDENCE; LIPIDS; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTMENOPAUSE; PRACTICE GUIDELINES; RISK; SINGLE-BLIND METHOD; TRIGLYCERIDES;

EID: 8144223376     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000146339.57154.9B     Document Type: Article

References (31)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem. 2001;47:1579-1596.
3. Sniderman AD. Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision-making. Clin Chem. 1997;43:1310-1314.
4. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol. 2002;90:48i-54i.
5. Rose G, Blackburn H. Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland: World Health Organization; 1982.
6. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119:837-839.
7. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
8. Stinshoff K, Weisshaar D, Stachler F, et al. Relation between concentration of free glycerol and triglycerides in human sera. Clin Chem. 1977;23:1029-1032.
9. Sugiuchi H, Uji Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated a-cyclodextrin. Clin Chem. 1995;41:717-723.
10. Rifai N, Iannotti E, DeAnagelis K, et al. Analytical and clinical performance of a homogenous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg+ + method. Clin Chem. 1998;44:1242-1250.
11. Darlington GA, Farewell VT. Regression modelling of HLA haplotype sharing in affected siblings. Biometrics. 1990;46:427-434.
12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
13. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523-1528.
14. Brown SA, Boerwinkle E, Kashanian FK, et al. Variation in concentration of lipids, lipoprotein lipids, and apolipoproteins A-I and B in plasma from healthy women. Clin Chem. 1990;36:207-210.
15. Pai JK, Curhan GC, Cannuscio CC, et al. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem. 2002;48:1781-1784.
16. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.
17. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
18. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
19. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-1113.
20. Gardner CD, Winkleby MA, Fortmann SP. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994). Am J Cardiol. 2000;86:299-304.
21. Gordon T, Castelli WP, Hjortland MP, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
22. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol. 1998;4(suppl A):5A-10A.
23. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol. 2002;90:77i-84i.
24. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
25. Kashyap ML, Tavintharan S, Kamanna VS. Optimal therapy of low levels of high-density lipoprotein-cholesterol. Am J Cardiovasc Drugs. 2003;3:53-65.
26. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
27. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 1988;29:1461-1473.
28. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis. 1991;89:109-116.
29. Lamarche B, Moorjani S, Lupien PJ, et al. Apoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Québec Cardiovascular Study. Circulation. 1996;94:273-278.
30. Veniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe-/- and Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2001;21:1567-1570.
31. Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003;146:227-233.